Skip to main content
Erschienen in: Clinical & Experimental Metastasis 3-4/2006

01.06.2006 | Original Paper

Diagnostic identification of malignant cells in the cerebrospinal fluid by tumor-specific qRT-PCR

verfasst von: Cristina Rosanda, Claudio Gambini, Barbara Carlini, Massimo Conte, Bruno De Bernardi, Alberto Garaventa, Maria Valeria Corrias

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 3-4/2006

Einloggen, um Zugang zu erhalten

Abstract

Tumor specific quantitative RT-PCRs for two neuroblastoma specific molecular markers, tyrosine hydroxylase (TH) and GD2 synthase, were used to unequivocally demonstrate the neoplastic nature of the cells present in the cerebrospinal fluid of a neuroblastoma patient. After radical surgery of two separate tumoral lesions, localized in the extradural area, the patient presented with meningitis. Common sites of neuroblastoma metastatization, e.g. bone and bone marrow, were not infiltrated by tumor cells, as assessed by standard scintigraphy, morphological investigation and by sensitive and specific immunocytochemical and molecular assays. The results presented here demonstrate the successful use of tumor-specific qRT-PCRs in cerebrospinal fluid to investigate questionable clinical cases. The technique, which compared to other detection methods (e.g., immunocytochemistry) requires very few cells, yields unambiguous information once a suspected diagnosis has been formulated and a tumor-specific molecular marker is available.
Literatur
1.
Zurück zum Zitat Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3(3):203–216PubMedCrossRef Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3(3):203–216PubMedCrossRef
2.
Zurück zum Zitat Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Edborg F (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11(8):1466–1477PubMed Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Edborg F (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11(8):1466–1477PubMed
3.
Zurück zum Zitat De Bernardi B, Pianca C, Boni L, Brisigotti M, Carli M, Bagnulo S, Corciulo P, Mancini A, De Laurentis C, Di Tullio MT (1992) Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Italian Cooperative Group on Neuroblastoma. Cancer 70(6):1625–1633PubMedCrossRef De Bernardi B, Pianca C, Boni L, Brisigotti M, Carli M, Bagnulo S, Corciulo P, Mancini A, De Laurentis C, Di Tullio MT (1992) Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Italian Cooperative Group on Neuroblastoma. Cancer 70(6):1625–1633PubMedCrossRef
4.
Zurück zum Zitat Matthay KK, Brisse H, Couanet D, Couturier J, Benard J, Mosseri V, Edeline V, Lumbroso J, Valteau-Couanet D, Michon J (2003) Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer 98(1):155–165PubMedCrossRef Matthay KK, Brisse H, Couanet D, Couturier J, Benard J, Mosseri V, Edeline V, Lumbroso J, Valteau-Couanet D, Michon J (2003) Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer 98(1):155–165PubMedCrossRef
5.
Zurück zum Zitat Kramer K, Kushner B, Heller G, Cheung NK (2001) Neuroblastoma metastatic to the central nervous system. Cancer 91(8):1511–1519CrossRef Kramer K, Kushner B, Heller G, Cheung NK (2001) Neuroblastoma metastatic to the central nervous system. Cancer 91(8):1511–1519CrossRef
6.
Zurück zum Zitat Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, Young B, Wailoo AJ, Burchill SA (2004) A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 10(1Pt1):4–12PubMedCrossRef Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, Young B, Wailoo AJ, Burchill SA (2004) A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 10(1Pt1):4–12PubMedCrossRef
7.
Zurück zum Zitat Cheung IY, Lo Piccolo MS, Collins N, Kushner BH, Cheung NK (2002) Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8. Cancer 94(11):3042–8PubMedCrossRef Cheung IY, Lo Piccolo MS, Collins N, Kushner BH, Cheung NK (2002) Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8. Cancer 94(11):3042–8PubMedCrossRef
8.
Zurück zum Zitat Cheung IY, Lo Piccolo MS, Kushner BH, Kramer K, Cheung NK (2003) Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol 21(6):1087–1093PubMedCrossRef Cheung IY, Lo Piccolo MS, Kushner BH, Kramer K, Cheung NK (2003) Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol 21(6):1087–1093PubMedCrossRef
9.
Zurück zum Zitat Trager C, Kogner P, Lindskog M, Ponthan F, Kullman A, Kagedal B (2003) Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow. Clin Chem 49(1):104–112PubMedCrossRef Trager C, Kogner P, Lindskog M, Ponthan F, Kullman A, Kagedal B (2003) Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow. Clin Chem 49(1):104–112PubMedCrossRef
10.
Zurück zum Zitat Ifversen MR, Kagedal B, Christensen LD, Rechnitzer C, Petersen BL, Heilmann C (2005) Comparison of immunocytochemistry, real-time quantitative RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma. Int J Oncol 27(1):121–129PubMed Ifversen MR, Kagedal B, Christensen LD, Rechnitzer C, Petersen BL, Heilmann C (2005) Comparison of immunocytochemistry, real-time quantitative RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma. Int J Oncol 27(1):121–129PubMed
11.
Zurück zum Zitat Swerts K, Ambros PF, Brouzes C, Navarro JM, Gross N, Rampling D, Schumaker-Kuckelkorn R, Sementa AR, Ladenstein R, Beiske K (2005) Standardization of the Immunocytochemical Detection of Neuroblastoma Cells in Bone Marrow. J Histochem Cytochem 53(12):1433–1440PubMedCrossRef Swerts K, Ambros PF, Brouzes C, Navarro JM, Gross N, Rampling D, Schumaker-Kuckelkorn R, Sementa AR, Ladenstein R, Beiske K (2005) Standardization of the Immunocytochemical Detection of Neuroblastoma Cells in Bone Marrow. J Histochem Cytochem 53(12):1433–1440PubMedCrossRef
12.
Zurück zum Zitat Peuchmaur M, d’Amore ES, Joshi VV, Hata J, Roald B, Dehner LP, Gerbing RB, Stram DO, Lukens JN, Matthay KK, Shimada H (2003) Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 98(10):2274–2281PubMedCrossRef Peuchmaur M, d’Amore ES, Joshi VV, Hata J, Roald B, Dehner LP, Gerbing RB, Stram DO, Lukens JN, Matthay KK, Shimada H (2003) Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 98(10):2274–2281PubMedCrossRef
13.
Zurück zum Zitat Gururangan S, McLaughlin C, Quinn J, Rich J, Reardon D, Halperin EC, Herndon J 2nd Fuchs H, George T, Provenzale J, Watral M, McLendon RE, Friedman A, Friedman HS, Kurtzberg J, Vredenbergh J, Martin PL (2003) High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. J Clin Oncol 21(11):2187–91PubMedCrossRef Gururangan S, McLaughlin C, Quinn J, Rich J, Reardon D, Halperin EC, Herndon J 2nd Fuchs H, George T, Provenzale J, Watral M, McLendon RE, Friedman A, Friedman HS, Kurtzberg J, Vredenbergh J, Martin PL (2003) High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. J Clin Oncol 21(11):2187–91PubMedCrossRef
14.
Zurück zum Zitat Perez-Martinez A, Quintero V, Vicent MG, Sevilla J, Diaz MA, Madero L (2004) High-dose chemotherapy with autologous stem cell rescue as first line of treatment in young children with medulloblastoma and supratentorial primitive neuroectodermal tumors. J Neuroncol 67(1–2):101–106CrossRef Perez-Martinez A, Quintero V, Vicent MG, Sevilla J, Diaz MA, Madero L (2004) High-dose chemotherapy with autologous stem cell rescue as first line of treatment in young children with medulloblastoma and supratentorial primitive neuroectodermal tumors. J Neuroncol 67(1–2):101–106CrossRef
15.
Zurück zum Zitat Goldsby RE, Matthay KK (2004) Neuroblastoma: evolving therapies for a disease with many faces. Paediatr Drugs 6(2):107–122PubMedCrossRef Goldsby RE, Matthay KK (2004) Neuroblastoma: evolving therapies for a disease with many faces. Paediatr Drugs 6(2):107–122PubMedCrossRef
16.
Zurück zum Zitat Schwab M, Westermann F, Hero B, Berthold F (2003) Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 4(8):472–480PubMedCrossRef Schwab M, Westermann F, Hero B, Berthold F (2003) Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 4(8):472–480PubMedCrossRef
17.
Zurück zum Zitat Berthold F, Hero B (2000) Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 59(6):1261–1277PubMedCrossRef Berthold F, Hero B (2000) Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 59(6):1261–1277PubMedCrossRef
18.
Zurück zum Zitat Nemecek ER, Sawin RW, Park J (2003) Treatment of neuroblastoma in patients with neurocristopathy syndromes. J Pediatr Hematol Oncol 25(2):159–162PubMedCrossRef Nemecek ER, Sawin RW, Park J (2003) Treatment of neuroblastoma in patients with neurocristopathy syndromes. J Pediatr Hematol Oncol 25(2):159–162PubMedCrossRef
19.
Zurück zum Zitat Kushner BH, Kramer K, LaQuaglia MP, Modak S, Cheung NK (2003) Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience. Med Pediatr Oncol 41(6):508–515PubMedCrossRef Kushner BH, Kramer K, LaQuaglia MP, Modak S, Cheung NK (2003) Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience. Med Pediatr Oncol 41(6):508–515PubMedCrossRef
Metadaten
Titel
Diagnostic identification of malignant cells in the cerebrospinal fluid by tumor-specific qRT-PCR
verfasst von
Cristina Rosanda
Claudio Gambini
Barbara Carlini
Massimo Conte
Bruno De Bernardi
Alberto Garaventa
Maria Valeria Corrias
Publikationsdatum
01.06.2006
Verlag
Kluwer Academic Publishers
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 3-4/2006
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-006-9032-z

Weitere Artikel der Ausgabe 3-4/2006

Clinical & Experimental Metastasis 3-4/2006 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.